{"title":"<i>Helicobacter pylori</i> in children: think before you kill the bug!","authors":"M Ravikumara","doi":"10.1177/17562848231177610","DOIUrl":null,"url":null,"abstract":"<p><p>Since the discovery of <i>Helicobacter pylori</i> (<i>H. pylori</i>) as the causative organism for gastric and duodenal ulcers four decades ago and subsequent recognition as class 1 gastric carcinogen, countless numbers of studies have been conducted and papers published, on the efficacy of various management strategies to eradicate the infection. In adults, a global consensus by the experts in the field concluded that <i>H. pylori</i> gastritis is an infectious disease and requires treatment irrespective of the presence or absence of symptoms due to the potential for serious complication like peptic ulcer disease and gastric neoplasia. However, although more than half the world's population harbors <i>H. pylori</i>, these serious complications occur only in a small minority of the infected population, even less so in childhood. More importantly, there is accumulating evidence for beneficial role of <i>H. pylori</i> against many chronic health conditions, from several epidemiological and laboratory studies. No doubt, eradication therapy is indicated in children with <i>H. pylori-</i>related peptic ulcer disease. Even though the pediatric guidelines from various learned societies recommend against a \"test and treat\" strategy, this is not always adhered to. With the accumulating evidence of the possible beneficial role of <i>H. pylori</i>, it is time to pause and think, are we causing more harm than good by eradicating <i>H. pylori</i> in every child who has this bug?</p>","PeriodicalId":23022,"journal":{"name":"Therapeutic Advances in Gastroenterology","volume":"16 ","pages":"17562848231177610"},"PeriodicalIF":4.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/93/bd/10.1177_17562848231177610.PMC10285598.pdf","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Gastroenterology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17562848231177610","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 3
Abstract
Since the discovery of Helicobacter pylori (H. pylori) as the causative organism for gastric and duodenal ulcers four decades ago and subsequent recognition as class 1 gastric carcinogen, countless numbers of studies have been conducted and papers published, on the efficacy of various management strategies to eradicate the infection. In adults, a global consensus by the experts in the field concluded that H. pylori gastritis is an infectious disease and requires treatment irrespective of the presence or absence of symptoms due to the potential for serious complication like peptic ulcer disease and gastric neoplasia. However, although more than half the world's population harbors H. pylori, these serious complications occur only in a small minority of the infected population, even less so in childhood. More importantly, there is accumulating evidence for beneficial role of H. pylori against many chronic health conditions, from several epidemiological and laboratory studies. No doubt, eradication therapy is indicated in children with H. pylori-related peptic ulcer disease. Even though the pediatric guidelines from various learned societies recommend against a "test and treat" strategy, this is not always adhered to. With the accumulating evidence of the possible beneficial role of H. pylori, it is time to pause and think, are we causing more harm than good by eradicating H. pylori in every child who has this bug?
自从40年前发现幽门螺杆菌(Helicobacter pylori, H. pylori)是胃和十二指肠溃疡的致病生物,并随后将其确定为1类胃癌致癌物以来,关于各种治疗策略根除幽门螺杆菌感染的疗效进行了无数的研究和论文发表。在成人中,该领域专家达成的全球共识是,幽门螺杆菌胃炎是一种传染病,由于可能出现消化性溃疡疾病和胃肿瘤等严重并发症,无论是否出现症状,都需要治疗。然而,尽管世界上一半以上的人口携带幽门螺旋杆菌,但这些严重的并发症只发生在一小部分受感染人群中,儿童期更少。更重要的是,从一些流行病学和实验室研究中,越来越多的证据表明幽门螺杆菌对许多慢性疾病有益。毫无疑问,根除治疗适用于幽门螺杆菌相关消化性溃疡疾病的儿童。尽管来自不同学术团体的儿科指南建议反对“检测和治疗”策略,但这并不总是被遵守。随着越来越多的证据表明幽门螺杆菌可能有益,是时候停下来思考一下了,我们在每个患有幽门螺杆菌的孩子身上根除幽门螺杆菌的做法是否弊大于利?
期刊介绍:
Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of gastrointestinal and hepatic disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in gastroenterology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area.
The editors welcome original research articles across all areas of gastroenterology and hepatology.
The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.